

This is a repository copy of *The utility of routine surveillance screening with magnetic resonance imaging to detect tumor recurrence/progression in children with high-grade central nervous system tumors : a systematic review.*

White Rose Research Online URL for this paper:

<https://eprints.whiterose.ac.uk/138650/>

Version: Published Version

Article:

Stevens, Simon P, Main, Caroline, Bailey, Simon et al. (9 more authors) (2018) The utility of routine surveillance screening with magnetic resonance imaging to detect tumor recurrence/progression in children with high-grade central nervous system tumors : a systematic review. *Pediatric blood & cancer*. e27509. e27509. ISSN 1545-5009

<https://doi.org/10.1002/pbc.27509>

Reuse

This article is distributed under the terms of the Creative Commons Attribution (CC BY) licence. This licence allows you to distribute, remix, tweak, and build upon the work, even commercially, as long as you credit the authors for the original work. More information and the full terms of the licence here:

<https://creativecommons.org/licenses/>

Takedown

If you consider content in White Rose Research Online to be in breach of UK law, please notify us by emailing eprints@whiterose.ac.uk including the URL of the record and the reason for the withdrawal request.

REVIEW

The utility of routine surveillance screening with magnetic resonance imaging to detect tumor recurrence/progression in children with high-grade central nervous system tumors: a systematic review

Simon P. Stevens¹ | Caroline Main¹ | Simon Bailey² | Barry Pizer³ |
 Martin English⁴ | Bob Phillips⁵ | Andrew Peet⁶ | Shivaram Avula³ | Sophie Wilne⁷ |
 Keith Wheatley¹ | Pamela R. Kearns^{1,4} | Jayne S. Wilson¹

¹Cancer Research UK Clinical Trials Unit (CRCTU), Institute of Cancer and Genomic Sciences, University of Birmingham, Birmingham, UK

²Sir James Spence Institute of Child Health, Royal Victoria Infirmary, Newcastle-Upon-Tyne, UK

³Alder Hey Children's NHS Foundation Trust, Liverpool, UK

⁴Birmingham Children's Hospital NHS Foundation Trust, Birmingham, UK

⁵Centre for Reviews and Dissemination (CRD), University of York, York, UK

⁶Institute of Cancer and Genomic Sciences, University of Birmingham, Birmingham, UK

⁷Queen's Medical Centre, Nottingham University Hospitals' NHS Trust, Nottingham, UK

Correspondence

Jayne Wilson, Cancer Research UK Clinical Trials Unit (CRCTU), Institute of Cancer and Genomic Sciences, University of Birmingham, Birmingham, UK.
 Email: j.s.wilson.1@bham.ac.uk

Abstract

Background: Surveillance magnetic resonance imaging (MRI) is routinely used to detect recurrence in children with high-grade central nervous system (CNS) tumors, although no consensus has been reached regarding its effectiveness and whether earlier detection is associated with improved patient outcomes. This review aimed to evaluate this practice and any associated benefits and harms.

Methods: Systematic searches for relevant studies were undertaken in a number of databases, including MEDLINE and EMBASE, from 1985 to August 2018. Study selection and data extraction was undertaken independently by two reviewers. Due to heterogeneity between studies, no pooling of data was undertaken. Reporting followed Preferred Reporting Items for Systematic Reviews and Meta-Analyses (PRISMA) guidelines.

Results: No comparative studies were identified. Three retrospective observational studies involving 306 patients were reviewed. All had high risk of bias by virtue of study design. Two studies reported outcomes by symptomatic status—both recurrence rates and overall survival for asymptomatic patients were comparable with those for clinically symptomatic patients. No quality-of-life outcomes were reported.

Conclusion: There is a paucity of evidence to guide clinical practice as to the effectiveness of MRI surveillance in pediatric patients with high-grade CNS tumors. These studies do not clearly demonstrate benefit or harm for the practice. With more research needed, there is a role for researchers to build into future trials data collection on surveillance imaging to give more information for the assessment of imaging frequency and duration in asymptomatic patients. This is an important question not only to clinicians and patients and their families but also from a health service resource perspective.

KEYWORDS

high-grade tumors, magnetic resonance imaging (MRI), pediatric CNS tumors, recurrence, surveillance, systematic review

1 | INTRODUCTION

Pediatric high-grade central nervous system (CNS) tumors are fast-growing, malignant tumors with metastatic potential and are commonly associated with poor prognosis even after multimodal treatment. Generally classified by the World Health Organisation (WHO)

as either grade III or IV tumors, they include glial (anaplastic astrocytoma and glioblastoma multiforme), ependymal (ependymoma, both WHO grade II and III), and embryonal (medulloblastoma and tumors previously known as primitive neuroectodermal tumors (PNET)) tumors, as well as brainstem tumors (diffuse pontine glioma (DIPG)), atypical teratoid/rhabdoid tumor (AT/RT), and pineoblastoma. Many

children with high-grade CNS tumors will go on to experience recurrence or progression, and the likelihood of this will depend on the histology and location of their first tumor, as well as treatments given.^{1,2}

In recent years, magnetic resonance imaging (MRI) has become the predominant imaging tool in the management of children with high-grade CNS tumors. The rationale behind routine imaging, or surveillance, is that recurrence or progressive disease detected at an earlier stage may be more responsive to treatment and benefit from a wider range of treatment options than disease diagnosed at a later stage from clinical signs and symptoms. However, no consensus has been reached as to whether this leads to improved outcomes for patients and their families.

The objectives of this review were therefore to:

1. assess the diagnostic utility of surveillance MRI in detecting tumor recurrence prior to the emergence of new clinical signs and symptoms compared with the non-routine use of MRI upon symptomatic presentation and assess whether this practice translates to measurable improvements in clinical outcomes;
2. consider the effect of differing screening intervals on the diagnostic utility of surveillance MRI and determine the optimal duration of imaging after initial diagnosis; and
3. identify any gaps and methodological weaknesses in the current evidence base and make recommendations to inform the design and analysis of future studies.

The authors have also undertaken a systematic review on the effectiveness of surveillance MRI in pediatric low-grade tumors, which forms a companion piece to this review paper.³

2 | METHODS

Standard systematic review methodology was employed and reporting followed the Preferred Reporting Items for Systematic Reviews and Meta-Analyses (PRISMA) guidelines.⁴ A detailed account of the methodology employed in this review can be found in the published protocol, which is also registered with PROSPERO (CRD 42016036802).⁵ A summary of the methods is described below.

2.1 | Search strategy

This review formed part of a wider NIHR-funded work program of systematic reviews aimed at assessing the effects of different interventions for the treatment of pediatric CNS tumors and therefore searches were not restricted to studies concerned solely with surveillance imaging in children with high-grade tumors. Searches for published studies from 1985 to August 2018 were undertaken in several databases, including MEDLINE and EMBASE (see Supporting Information File S1). No language, publication restrictions, or study design filters were applied.

2.2 | Study selection

The following inclusion and exclusion criteria were applied:

Population: Children and young adults (up to age 25 years) with diagnoses of any type of high-grade CNS tumor who were asymptomatic at the time of study recruitment. Given that children undergoing surveillance may have some neurologic sequelae from their tumor and/or its treatment, it would be more accurate to characterize patients as exhibiting no new, stable, or improved neurological signs or symptoms.

Interventions: Routine or surveillance MRI. Studies employing computed tomography (CT) as the sole surveillance imaging modality were excluded.

Outcome measures: These included recurrence rates (by study, tumor type, location, and extent of resection), diagnostic yield of imaging, timing of recurrence, change in patient management postrecurrence, overall survival (OS), surrogate survival measures (e.g., recurrence-free survival, progression-free survival (PFS)), and quality of survival. Studies reporting outcomes from aggregated CT and MRI scans were excluded.

Study designs: As randomized controlled trials (RCTs) and nonrandomized comparative studies were initially sought but not identified, the review was extended to include observational studies such as case series.

Study selection was undertaken by two independent reviewers, with disagreements resolved by discussion.

2.3 | Data extraction and risk of bias assessment

Data, extracted by one reviewer and checked by a second, were recorded on a standardized proforma developed in Microsoft Word (see Supporting Information File S2). Risk of bias was assessed at the study level by two reviewers using a six-point tool devised by the Centre for Reviews and Dissemination (York; CRD)⁶ designed to assess bias in case series studies.

2.4 | Statistical analysis

Due to the design of the included studies and the heterogeneity of outcomes reported, only a descriptive analysis was undertaken.

3 | RESULTS

3.1 | Quantity and description of included studies

From the electronic database searches, 28 potentially relevant publications were identified, with an additional 13 publications identified from citation-checking. On full-text examination, 38 were excluded, including 11 studies that employed both CT and MRI as surveillance imaging modalities but failed to report results separately for MRI (see Supporting Information File S3). No RCTs or prospective comparative studies were identified. Three retrospective case series studies⁷⁻⁹ were included in the review (see Figure 1).




FIGURE 1 PRISMA diagram of flow of studies through the selection process

The three studies were conducted between 2001 and 2014 and undertaken at single-center institutions. Two studies^{8,9} included patients with high-grade tumors only, with one⁷ including a mix of low- and high-grade tumor patients (see Table 1).

3.2 | Quality of the research

Studies were clinically heterogeneous with study populations varying in terms of both tumor type and disease severity. Study samples were small but patients appeared to be representative of the target population, although it was unclear whether patients were at a similar time point in the disease progression. Inclusion and exclusion criteria for each study were explicitly stated. Generally, details of previous treatments were not reported (see Supporting Information File S4). There was also variability in terms of reporting and defining of outcomes. The terms “recurrence” and “progression” were defined in all three studies, although only two reported recurrences as “symptomatic” and “asymptomatic” and defined these terms.^{7,9} All three studies reported OS, although only Kornreich⁸ defined the term (see Supporting Information Table S5). This was also the only study to report PFS. Korones⁷ did not report average duration of follow-up.

3.3 | Included studies

3.3.1 | Korones (2001)⁷

Korones⁷ was a mixed tumor grade study with 112 children at study commencement. Patient details were provided only for the 46 patients who went on to experience recurrence/progression. Of these, 33 had high-grade tumors. Eight tumor types were included. The median age of these patients at recurrence was six years (range, 0.25–21), although this was not reported by tumor type.

All patients underwent surgery as the primary treatment, although this was not further specified by extent of resection (i.e., gross total resection (GTR) vs subtotal resection (STR)). At the commencement of surveillance imaging, none of the patients had relapsed disease.

With respect to imaging frequency, patients received a median of one scan every 2.5 months (range, 1/1 to 1/6.7 months) irrespective of whether they were symptomatic or asymptomatic at recurrence. Frequency of scanning was not reported by tumor type.

As only data on recurrent patients were reported, it was not possible to calculate the recurrence rate for the 33 high-grade tumor patients as a whole, nor by tumor type. The rate of recurrence/progression by symptomatic status was reported, with 17 patients (52%) asymptomatic at recurrence. Recurrence by symptomatic status was also reported by tumor type, with asymptomatic and symptomatic recurrences comparable in number, although the numbers in each category were very small (ranging from 1 to 6) (see Table 2). Recurrence by extent of resection was not reported.

The diagnostic yield of imaging for all 17 asymptomatic patients was 4.4%, i.e., one asymptomatic recurrence detected every 23 MRI scans (see Table 2). With respect to choroid plexus carcinoma (CPC), germ cell tumor (GCT), and AT/RT, there were two asymptomatic recurrences among these tumor types, and the diagnostic yield of imaging was 6.5%.

The median time to recurrence from initial diagnosis for all 33 patients was 0.75 years, with no significant difference in median time to recurrence between symptomatic and asymptomatic patients at recurrence (0.66 and 0.77 years, respectively). The median time to recurrence was not reported by individual tumor type, nor by extent of resection.

Information regarding local therapy received following recurrence/progression was provided for 26 patients (79%), with 8 of 14 asymptomatic patients (57%) undergoing local therapy (surgery with or without stereotactic radiosurgery) compared with only 3 of 12 symptomatic patients (25%) ($P = 0.13$). Again, change in patient management was not reported by tumor type.

Overall survival from recurrence for all 33 patients was reported but only by symptomatic status at recurrence, with median OS for the 17 asymptomatic patients (0.58 years) marginally and nonstatistically significantly greater ($P = 0.25$) than that for the 16 symptomatic patients (0.42 years). Median OS was not reported by tumor type.

3.3.2 | Kornreich (2005)⁸

Kornreich⁸ was a retrospective case series study looking at the role of surveillance MRI in the management of 15 pediatric patients with DIPG. Although the frequency of imaging was not reported, the mean number of MRI scans per patient was six. Thirteen patients (87%) experienced tumor progression, while two patients remained stable. Symptomatic status of patients at progression was not reported.

Median PFS was 0.83 years, ranging from zero months (in four patients who deteriorated immediately from diagnosis without any prior period of stability) to nine years. Treatment (radiotherapy and/or chemotherapy) was planned and not consequent to changes in scans or

TABLE 1 Characteristics of included studies

Study (year) (ref) Location Years of study	Aim Study design	Population	Intervention	Outcomes reported
Korones et al (2001) ⁷ USA 1990–1999	To determine the frequency of detection of recurrent/progressive brain tumors in asymptomatic children are detected by surveillance MRI scans and to compare the survival of children with asymptomatic recurrence compared with those whose recurrences are detected by symptoms Retrospective case series study	Included: Patients with a brain tumor aged <21 at diagnosis and for whom neuroimaging surveillance was performed exclusively by MRI. Excluded: Patients with spinal cord tumors or children followed by CT scans. Tumor type: Both low- and high-grade tumors, including 33 (72%) recurrent high-grade tumors including: - HGG (anaplastic astrocytoma, glioblastoma multiforme): $n = 10$ (30%) - Brainstem glioma: $n = 7$ (21%) - sPNET: $n = 5$ (16%) - MB: $n = 4$ (12%) - Epend: $n = 4$ (12%) - CPC: $n = 1$ (3%) - GCT: $n = 1$ (3%) - AT/RT: $n = 1$ (3%) $N = 112$ (although the paper focuses exclusively on the 46 recurrent patients) Male: 45% Median age at diagnosis ($n = 46$): 6.5 years (0.25–21) Median age at recurrence for 33 high-grade patients: 6 years (0.25–21) Average follow-up: NR Tumor location: NR Previous treatment(s): - Surgery: $n = \text{NR}$	Surveillance MRI. Details: • MRI scanner: No details. • Image sequences taken: No details. • Imaging schedule: 1 scan every 2.5 months (range, 1/1 month to 1/6.7 months). • Average number of MRI images per patient: NR for high-grade tumor patients only. Surveillance MRI: “Scans done ≥ 1 month after surgery (or > 1 month after the original diagnostic MRI if diagnosis was by MRI only) were considered surveillance scans. Immediate postoperative MRI scans were not considered surveillance scans.”	<ul style="list-style-type: none"> • Recurrence by symptomatic status • Median time from diagnosis to recurrence by tumor grade • Median OS by symptomatic status for all patients • Median OS for symptomatic status for high-grade tumor patients • Overall survival ($n = 46$) • 2-year OS from time of recurrence by symptomatic status
Kornreich et al (2005) ⁸ Israel 1985–2001	To describe the MR findings of pontine tumors at diagnosis and during follow-up and correlate those with prognosis and to assess the value of MR imaging in patient management compared with clinical evaluation. Retrospective case series study	Included: Patients with a DIPG “according to the classification of Barkovich et al (center of the mass in the pons, involving $> 50\%$ of the axial area) who underwent MR imaging at diagnosis and at least once during treatment.” Excluded: NR Tumor grade: only pathologically confirmable in the 3 patients who underwent surgery at diagnosis: - glioblastoma multiforme ($n = 1$) - astrocytoma grade II ($n = 1$) - astrocytoma grade III ($n = 1$) Tumor location: “center of the mass in the pons, involving $> 50\%$ of the axial area” $N = 15$ Male: 73% Median age at diagnosis: 5.6 years (range, 2–19) Average follow-up: - Median: 1.5 years ^a (range, 0.17–9) - Mean: 2.17 years Previous treatment(s): - Surgery ($n = 3$ patients with a posterior cystic exophytic component underwent surgery at diagnosis)	Surveillance MRI Details: • MRI scanner: No details. • Image sequences taken: All patients underwent at least T1-weighted (T1W) sagittal and T1W and T2W axial sequences, with contrast agent (gadopentate dimeglumine) used in all cases.	<ul style="list-style-type: none"> • Progression rate • Medium time to progression • Median OS • Median PFS • Tumor response rates • Changes in patient treatment due to progression

(Continues)

TABLE 1 (Continued)

Study (year) (ref) Location Years of study	Aim Study design	Population	Intervention	Outcomes reported
Perreault et al (2014) ⁹ USA 2000–2011	To assess the benefits of surveillance MRI and more specifically spine MRI in a contemporary cohort. Retrospective case series study	Included: Patients "with at least one surveillance MRI following the diagnosis of MB, AT/RT, PB, (s)PNET, (s)HGG (WHO grades III and IV), CNS GCT or Epend." Excluded: Patients with "a malignant CNS tumor involving only the spine at diagnosis." N = 258 Male: 62% Median age at diagnosis: 8 years (range, 0.3–21) Median follow-up (n = 258): 3.12 years (range, 0.13–11.8) Tumor type(s): Mixed: - MB: n = 89 (35%) - AT/RT: n = 10 (4%) - PB: n = 9 (3%) - sPNET: n = 25 (10%) - HGG: n = 34 (13%) - GCT: n = 39 (15%) - Ependymoma: n = 52 (20%) Tumor grade: - HGG: WHO grade III–IV - GCT: WHO grades II and III - Epend: WHO grades II and III Tumor location: Supratentorial (reported for PNET and HGG only) Previous treatment(s): NR	Surveillance MRI. Details: • No details of the MRI scanner used or the image sequences taken.	<ul style="list-style-type: none"> Median follow-up; total and by tumor type Median number of scans (range); total and by tumor type Recurrence rate; total and by tumor type, and by first and subsequent recurrences Symptomatic status at recurrence Median time to recurrence; total and by tumor type, and by symptomatic status at recurrence Median OS by symptomatic status at recurrence Frequency of MRI-detected recurrence; total and by tumor type Changes in patient treatment due to recurrence after first relapse

Abbreviations: AT/RT, atypical teratoid/rhabdoid tumor; CPC, choroid plexus carcinoma; DIPG, diffuse pontine glioma; Epend, ependymoma; GCT, germ cell tumor; HGG, high-grade glioma; MB, medulloblastoma; MRI, magnetic resonance imaging; PB, pineoblastoma; N, number of patients; N/A, not applicable; ND, not defined; NR, not reported; (s)HGG, (supratentorial) high-grade glioma; (s)PNET, (supratentorial) primitive neuroectodermal tumor; WHO: World Health Organization.

^aNot directly reported by the authors but calculated by the reviewer based on data reported in the publication.

TABLE 2 Summary of radiographic outcomes by tumor type for 33 high-grade tumor patients in Korones⁷

Tumor type	N (recurrent patients only)	Median frequency of imaging in months (range)	Patients with recurrent disease n (%)		Diagnostic yield of MRI ^c (%)	Median time to recurrence in years (range)	Median time to recurrence in years (range)	
			Asymp	Symp			Asymp	Symp
Total	33	1 scan/2.5 (1/1–1/6.7)	17 (52)	16 (48)	4.4 (656 scans)	0.75 (0.17–6)	0.75 (0.17–4.33)	0.67 (0.17–6)
HGG	10	NR	4 (40)	6 (60)	6.3 (63 scans)	NR	NR	NR
DIPG	7	NR	3 (43)	4 (57)	15.3 (19 scans)	NR	NR	NR
sPNET ^a	5	NR	3 (60)	2 (40)	7.2 (42 scans)	NR	NR	NR
MB	4	NR	2 (50)	2 (50)	1.4 (147 scans)	NR	NR	NR
Epend	4	NR	3 (75)	1 (25)	3.5 (86 scans)	NR	NR	NR
Other ^b	3	NR	2 (67)	1 (33)	6.5 (31 scans)	NR	NR	NR

Abbreviations: asymp, asymptomatic; DIPG, diffuse pontine glioma; epend, ependymoma; GCT, germ cell tumor; HGG, high-grade glioma; MB, medulloblastoma; N, number of patients; sPNET, supratentorial primitive neuroectodermal tumor; symp, symptomatic.

^aAs of 2016, the term PNET no longer appears in the current WHO classification of CNS tumors.

^b"Other" includes choroid plexus carcinoma (n = 1), germ cell tumor (n = 1), and atypical teratoid/rhabdoid tumor (n = 1).

^cAsymptomatic recurrence only.

recurrence. Median OS was 1.67 years, with three patients (20%) alive at the time of reporting.

3.3.3 | Perreault (2014)⁹

Perreault⁹ was a retrospective case series study that sought to assess the benefits of surveillance MRI in a cohort of 258 high-grade tumor

patients. Seven tumor types were included (see Table 1). All patients underwent surgery as the primary treatment, although this was not further specified by extent of resection. At commencement of surveillance imaging, none of the patients had relapsed disease.

Although frequency of scanning was not reported, the median number of MRI scans per patient across all tumor types was

13, 10 of the brain and three spinal (see Table 3). The interval since last MRI for symptomatic patients was not longer for symptomatic compared with asymptomatic patients (mean, 3.9 vs 4.8 months).

Rates of recurrence/progression were also reported by symptomatic status (see Table 3). With respect to first recurrences ($n = 113$), there was a slight predominance of asymptomatic (46%) compared with symptomatic recurrences (42%), whereas for subsequent recurrences ($n = 125$) the converse was the case (29% vs 58%). Recurrences (both first and subsequent) by symptomatic status were also reported by tumor type where, in the case of medulloblastoma and ependymoma, this trend continued with the majority of first recurrences asymptomatic and second symptomatic. Conversely, for supratentorial primitive neuroectodermal tumor (sPNET), the majority of first recurrences were symptomatic and second asymptomatic. For HGG, the majority of both first and second recurrences were symptomatic. For the remaining tumor types (GCT, AT/RT, and pineoblastoma), the number of recurrences was so small that caution should be exercised when comparing recurrences by symptomatic status (most notably AT/RT, with 100% of first recurrences asymptomatic based on only four patients). Recurrences among glioma patients were more frequently symptomatic compared with those patients with other tumor types (68% vs 38%, respectively; $P = 0.003$). The rate of recurrence by extent of resection was not reported.

A breakdown of MRI scans by both tumor type and site of imaging was reported, with diagnostic yield across all tumor types of 8.3% for brain recurrence only (range, 2.1%–21.6%), 3.8% for combined brain–spine recurrence (range, 1.6%–19.7%), and 0.9% for spine recurrence only (range, 0.7%–4.9%) (see Table 3).

The median time to recurrence from initial diagnosis was 1 year, although it is unclear whether this relates to first recurrence or all recurrences. The median time to recurrence by tumor type was reported but, again, it is unclear if this relates to first recurrence or all recurrences (see Table 3). No significant difference in median time to recurrence was reported between symptomatic and asymptomatic patients at recurrence (1.0 and 0.92 years, respectively; $P > 0.8$). The time by which greater than 90% of recurrences had occurred for each individual tumor type was also reported (see Table 3). Median time to recurrence by extent of resection was not reported.

Change in patient management following first recurrence was reported for 93% of patients, with 59% of patients undergoing new treatments, 11% continuing with existing treatment, 16% scheduled for palliative care, and 7% undergoing closer interval surveillance MRI. New treatments consisted of chemotherapy (22% standard dose and 4% high dose with stem cell support), radiotherapy (6%), radio-surgery (2%), surgery (5%), and unspecified multimodal therapy (20%). Change in patient management postrecurrence by tumor type was not reported.

There was no significant difference ($P > 0.3$) in median OS from recurrence between symptomatic and asymptomatic patients (1.92 and 2.25 years, respectively). Median OS by tumor type was not reported.

TABLE 3 Summary of radiographic outcomes by tumor type in Perreault^a

Tumor type	N	Median follow-up in years	Median no. of MRI scans per patient in years	First recurrence ($n = 113$)			Subsequent recurrence ($n = 125$)			Diagnostic yield of surveillance MRI (%)			Median time to recurrence in years (range)	Time to > 90% of recurrences in years
				Asymp N (%)	Symp N (%)	Unknown N (%)	Asymp N (%)	Symp N (%)	Unknown N (%)	B	B/S	S		
Total	258	3.13	13	52 (46)	47 (42)	14 (12)	36 (29)	58 (46)	31 (25)	8.3	3.8	0.9	1.0 (0.03–11.4)	2.83
MB	89	4.33	18.5	17 (63)	6 (22)	4 (15)	6 (21)	12 (41)	11 (38)	5.2	2.5	0.7	1.3 (0.04–6.3)	2.17
Epend	52	3.96	11	12 (46)	7 (27)	7 (27)	10 (26)	15 (38)	14 (36)	11.3	4.3	1.1	1.3 (0.08–5.4)	3.0
GCT	39	4.25	15	5 (56)	4 (44)	0 (0)	1 (50)	1 (50)	0 (0)	2.1	2.4	1.6	3.17 (0.08–11.4)	8.1
HGG	34	1.25	6	7 (25)	19 (68)	2 (7)	5 (19)	19 (73)	2 (8)	21.6	11.4	2.8	0.88 (0.07–3.17)	2.25
sPNET ^a	25	3.75	17	5 (36)	8 (57)	1 (7)	11 (58)	6 (32)	2 (10)	10.5	1.6	0	0.96 (0.03–4.5)	2.42
AT/RT	10	0.54	7	4 (100)	0 (0)	0 (0)	2 (67)	1 (33)	0 (0)	10.9	13	0	0.46 (0.42–0.75)	0.75
PB	9	2.08	16	2 (40)	3 (60)	0 (0)	1 (14)	4 (57)	2 (29)	9.3	19.7	4.9	1.67 (0.92–2.5)	2.5

Abbreviations: Asymp, asymptomatic; AT/RT, atypical teratoid/rhabdoid tumor; B, brain only; B/S, combined brain and spine; Epend, ependymoma; FU, follow-up; GCT, germ cell tumor; HGG, high-grade glioma; MB, medulloblastoma; MB, medulloblastoma; N, number of patients; PB, pineoblastoma; sPNET, supratentorial primitive neuroectodermal tumor; s, spine only; symp, symptomatic.

^aAs of 2016, the term PNET no longer appears in the current World Health Organization classification of CNS tumors.

4 | DISCUSSION

This systematic review is one of a series evaluating treatments for children with CNS tumors. Underpinning the reviews was consultation with clinical experts and a patient and public involvement (PPI) group, consisting of mothers of children with CNS tumors. The PPI group in particular expressed concerns about overscanning, especially in situations where scanning is no longer able to influence prognosis as in the case of patients for which nothing further can be clinically done. As well as the unknown risks associated with repeated administration of contrast materials such as gadolinium,¹⁰ anesthesia, and sedatives, the PPI group spoke of what has come to be termed “scanxiety,” i.e., an overwhelming feeling of stress experienced by both patient and family around the time of scanning. As one parent put it: “At times, it seems like life and all its decisions revolve around scanning, which serves as a constant reminder of the cancer and acts as an obstacle to resuming normal behaviour.”

Although the use of surveillance MRI is standard practice throughout the developed world in the management of children with high-grade CNS tumors, this systematic review did not identify any RCTs evaluating this intervention. After excluding 11 high-grade tumor surveillance imaging studies which employed both CT and MRI but did not report results separately by imaging modality,^{11–21} the review included three retrospective, single-arm studies ($n = 306$ patients) with MRI employed as the sole imaging modality. It could be argued that in excluding studies employing CT imaging, the review has lost valuable data on surveillance. However, the reason for focusing on MRI, other than its superior sensitivity, is that MRI studies are more recent than CT studies and therefore encompass an era of improved survival and greater salvageability of patients due to improved treatments.

The findings of the review were mixed. Korones⁷ concluded that “asymptomatic recurrences were detected in only a small proportion of surveillance scans and had no impact on survival in children with high-grade tumours.” Kornreich⁸ reported on 15 patients with DIPG and compared the findings of 51 surveillance scans with those from clinical examination and reported a high degree of concordance (87%), suggesting that for DIPG, surveillance MRI is providing little information over and above that conveyed by clinical symptoms and signs and therefore its utility may be limited. Ultimately, surveillance imaging did not affect the treatment given, nor the outcome. On the basis of this evidence, it could be argued, albeit tentatively, that certain tumor types may be more amenable to surveillance MRI than others and that for aggressive tumors such as DIPG, where often any period of clinical stability is extremely limited, there is a very short window of opportunity for surveillance imaging to exploit. In support of this, Kornreich⁸ reported four patients with zero time to progression. However, with other, less aggressive high-grade tumor types, the use of MRI surveillance may be of value. For example, with Perreault,⁹ asymptomatic recurrence rates were higher for ependymoma and medulloblastoma compared with other tumor types, suggesting that surveillance might potentially be beneficial to these patients, although in this study asymptomatic patients across all tumor types did not benefit from improved OS compared with symptomatic patients.

Unfortunately, the potential for bias within case series is considerable, and therefore conclusions from this review are tentative and should be viewed with extreme caution.

There were several reporting problems that made comparison across the studies problematic. Korones failed to report frequency of MRI imaging by tumor grade or type, thereby rendering a cross-study comparison of the effect of differing imaging schedules on the rate of asymptomatic recurrence for different tumor types impossible.⁷ Similarly, Kornreich⁸ did not report patients by symptomatic status at time of progression. Only Perreault⁹ reported patients and recurrences by tumor type and symptomatic status, enabling observations to be drawn that could potentially inform the design of future trials. However, it is important to appreciate that the data analyzed in these studies were acquired for clinical purposes for which assessment of surveillance imaging protocols was not an objective.

The initial aim of this review was to assess the effectiveness of surveillance MRI. RCTs were required to do this, but as none were found, the focus was switched to finding studies that were specifically conducted to describe surveillance scanning. With just three studies meeting the inclusion criteria, one criticism of this review that emerged from the peer review process was that the cooperative trials should have been hand-searched for information on surveillance. This raises an interesting point about the best way to systematically review pediatric oncology trials. Systematic reviewing (especially employing Cochrane methodology) was developed with single-question trials involving more common diseases in mind, i.e., A versus B, whereas pediatric oncology trials tend to be cooperative, multimodal trials that attempt to answer a variety of questions within a single trial due to the rarity of the diseases. In response to the peer review feedback, a search of cooperative trials in medulloblastoma was undertaken to determine whether there were data within these trials to inform the review question. Of 27 trials, surveillance MRI scanning intervals appeared to be arbitrary and variable, with few reasons given for the surveillance schedules (see Supporting Information File S6). Only one study, not identified in our systematic review searches likely due to indexing, evaluated the number of patients who had relapse detected through surveillance MRI compared with symptom-based relapse.²² This study reported that 45 relapses were detected on surveillance MRI, with 20 detected from symptoms alone. Of these, patients detected from symptoms had a significantly shorter survival postrelapse than those detected by surveillance MRI ($P < 0.01$), although OS postprimary diagnosis was not statistically significantly different. This could be due to lead time bias or that patients in the symptomatic relapse group possibly have more aggressive tumors. Finding the evidence in a systematic way, from identifying the relevant publications to finding the information within the trial publications (often results are written into the discussions) can be challenging in these large cooperative trials. In the future, we recommend that systematic reviewers consider hand-searching relevant cooperative trials, while bearing in mind that the main aim of these trials might differ from that of the systematic review. We also urge authors of cooperative trials to improve the transparency of their publications, especially with respect to database indexing as well as signposting and organization of information within the papers.

The paucity of data evidenced in this review may be due to the complexity of surveillance in these patients, with frequency of monitoring depending on tumor type, disease status (newly diagnosed, resistant or relapsed), extent of metastatic spread, and previous treatments. Other factors such as pseudoprogression and radiation necrosis can also complicate the interpretation of scans, making it a difficult area to investigate. However, there is a need to examine this question further in order to guide clinicians in developing optimal evidence-based surveillance strategies, to help parents and children understand the need for surveillance, and to optimize the use of health service resources. There is a role for researchers to build into future, large cooperative trials methodology that investigates the role of surveillance MRI or, at the very minimum, collects and reports data on the trial surveillance MRI practice, as well as incorporating quality-of-life data collection, particularly regarding anxiety around surveillance and the reassurance that it may also afford.

5 | CONCLUSION

Only three retrospective observational studies with a high risk of bias were identified to guide clinical practice of surveillance MRI for children with high-grade CNS tumors.⁷⁻⁹ These studies do not clearly demonstrate benefit or harm for this practice, nor do they define methods or intervals for maximal effectiveness. To resolve this, more research is needed with the ultimate endpoints of surveillance relating to survival and quality of life, as opposed to surrogate outcomes such as the detection of tumor growth. As most of the patients within this group are treated within the context of a cooperative clinical trial, this research could be built into trial protocols for very little extra investment. It is an important question, not only to clinicians and patients and their families but also as a health service resource question.

COMPLIANCE WITH ETHICAL STANDARDS

Informed consent: Not required for this type of study (i.e., systematic review). Ethical approval: Not required for this type of study (i.e., systematic review). Research involving human participants and/or animals: This article does not contain any studies with human participants or animals performed by any of the authors.

AUTHORS' CONTRIBUTIONS

SPS conceived and designed the study and wrote the article. CM conceived and designed the study and read and commented on the article. SB, BP, ME, and RP conceived the study concept, provided clinical input, and read and commented on the article. AP, SA, SW, and PRK provided clinical input and read and commented on the article. KW conceived and designed the study, provided methodological and statistical input, and read and commented on the article. JSW conceived and designed the study, revised the article, and is the guarantor of the review. All the authors read and approved the final manuscript.

ACKNOWLEDGMENTS

We would like to acknowledge the input of the patient and public involvement (PPI) group and the wider clinical team who helped

to frame the review question and contribute to the direction of the paper.

CONFLICTS OF INTEREST

The authors declare that they have no conflict of interest.

FUNDING

This paper presents independent research funded by the National Institute for Health Research (NIHR) under its Research for Patient Benefit (RfPB) Programme (Grant Reference Number PB-PG-1112-29122). PK, KW, and JW received funding from Cancer Research UK. AP is funded by an NIHR Research Professorship (13-0053). The views expressed are those of the author(s) and not necessarily those of the NHS, the NIHR, the Department of Health and Social Care or Cancer Research UK.

ORCID

Simon P. Stevens  <http://orcid.org/0000-0002-3145-836X>

REFERENCES

1. Elterman RD, Bruce DA. The continued surveillance for recurrent medulloblastoma/primitive neuro-ectodermal tumor (abstract). *Pediatr Neurosurg*. 1993;19:322.
2. Kramer ED, Vezina LG, Packer RJ, Fitz CR, Zimmerman RA, Cohen MD. Staging and surveillance of children with central nervous system neoplasms: recommendations of the neurology and tumor imaging committees of the Children's Cancer Group. *Pediatr Neurosurg*. 1994;20:254-263.
3. Stevens SP, Main C, Bailey S, et al. The utility of routine surveillance screening with magnetic resonance imaging (MRI) to detect tumour recurrence in children with low-grade central nervous system (CNS) tumours: a systematic review. *J Neurooncol*. 2018. <https://doi.org/10.1007/s11060-018-2901-x>
4. Moher D, Liberati A, Tetzlaff J, Altman DG. Preferred reporting items for systematic reviews and meta-analyses: the PRISMA statement. *Ann Intern Med*. 2009;151:264-269.
5. Main C, Stevens SP, Bailey S, et al. The impact of routine surveillance screening with magnetic resonance imaging (MRI) to detect tumour recurrence in children with central nervous system (CNS) tumours: protocol for a systematic review and meta-analysis. *Syst Rev*. 2016;5:143.
6. NHS Centre for Reviews and Dissemination: Undertaking Systematic Reviews of Research on Effectiveness. CRD Guidelines for Those Carrying Out or Commissioning Reviews. Report 4 (1996) York Publishing Services Ltd.
7. Korones DN, Butterfield R, Meyers SP, Constine LS. The role of surveillance magnetic resonance imaging (MRI) scanning in detecting recurrent brain tumors in asymptomatic children. *J Neurooncol*. 2001;53:33-38.
8. Kornreich L, Schwarz M, Karmazyn B, et al. Role of MRI in the management of children with diffuse pontine tumors: a study of 15 patients and review of the literature. *Pediatr Radiol*. 2005;35:872-879.
9. Perreault S, Lober RM, Carret A-S, et al. Surveillance imaging in children with malignant CNS tumors: low yield of spine MRI. *J Neurooncol*. 2014;116:617-623.
10. Khawaja AZ, Cassidy DB, Al Shakarchi J, McGrogan DG, Inston NG, Jones RG. Revisiting the risks of MRI with gadolinium based

- contrast agents-review of literature and guidelines. *InsightsImaging*. 2015;6:553–558.
11. Roebuck JD, Villablanca GJ, Maher K, Nelso, DM, Jr. Surveillance imaging in children with medulloblastoma (posterior fossa PNET). *Pediatr Radiol*. 2000;30:447–450.
 12. Saunders DE, Hayward RD, Phipps KP, Chong WK, Wade AM. Surveillance neuroimaging of intracranial medulloblastoma in children: how effective, how often, and for how long. *J Neurosurg*. 2003;99:280–286.
 13. Shaw DWW, Geyer JR, Berger MS, Milstein J, Lindsley KL. Asymptomatic recurrence detection with surveillance scanning in children with medulloblastoma. *J Clin Oncol*. 1997;15:1811–1813.
 14. Good CD, Wade AM, Hayward RD, et al. Surveillance neuroimaging in childhood intracranial ependymoma: how effective, how often, and for how long. *J Neurosurg*. 2001;94:27–32.
 15. Mendel E, Levy ML, Raffel C, et al. Surveillance imaging in children with primitive neuroectodermal tumors. *Neurosurgery*. 1996;38:692–695.
 16. Torres CF, Rebsamen S, Silber JH, et al. Surveillance scanning of children with medulloblastoma. *New Engl J Med*. 1994;330:892–895.
 17. Kovanlikaya A, Karabay N, Çakmakçı H, Uysal K, Olgun N, Ergör G. Surveillance imaging and cost effectivity in pediatric brain tumors. *Eur J Radiol*. 2003;47:188–192.
 18. Minn AY, Pollock BH, Garzarella L, et al. Surveillance neuroimaging to detect relapse in childhood brain tumors: a Pediatric Oncology Group study. *J Neurooncol*. 2001;19:4135–4140.
 19. Steinbok P, Hentschel S, Cochrane DD, Kestle JR. Value of postoperative surveillance imaging in the management of children with some common brain tumors. *J Neurosurg*. 1996;84:726–732.
 20. Yalçın B, Büyükpamukçu M, Akalan N, Cila A, Kutluk MT, Akyüz C. Value of surveillance imaging in the management of medulloblastoma. *Med Pediatr Oncol*. 2002;38:91–97.
 21. Hirpara DH, Bhatt MD, Katrin S. Utility of long-term surveillance neuroimaging five years post-diagnosis in the management of pediatric brain tumours. *Austin Pediatr Oncol*. 2016;1:1002.
 22. Sabel M, Fleischhack G, Tippelt S, et al. Relapse patterns and outcome after relapse in standard risk medulloblastoma: a report from the HIT-SIOP-PNET4 study. *J Neurooncol*. 2016;129:515–524.

SUPPORTING INFORMATION

Additional supporting information may be found online in the Supporting Information section at the end of the article.

How to cite this article: Stevens SP, Main C, Bailey S, et al. The utility of routine surveillance screening with magnetic resonance imaging to detect tumor recurrence/progression in children with high-grade central nervous system tumors: a systematic review. *Pediatr Blood Cancer*. 2018; e27509. <https://doi.org/10.1002/pbc.27509>